Advertisement
UK markets close in 7 hours 15 minutes

  • FTSE 100

    8,075.96
    +35.58 (+0.44%)
     

  • FTSE 250

    19,633.99
    -85.38 (-0.43%)
     

  • AIM

    753.93
    -0.76 (-0.10%)
     

  • GBP/EUR

    1.1666
    +0.0021 (+0.18%)
     

  • GBP/USD

    1.2513
    +0.0050 (+0.40%)
     

  • Bitcoin GBP

    51,197.48
    -2,195.47 (-4.11%)
     

  • CMC Crypto 200

    1,331.41
    -51.16 (-3.70%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.12
    +0.31 (+0.37%)
     

  • GOLD FUTURES

    2,341.00
    +2.60 (+0.11%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,269.04
    +67.77 (+0.39%)
     

  • DAX

    18,002.29
    -86.41 (-0.48%)
     

  • CAC 40

    8,068.50
    -23.36 (-0.29%)
     
Property:

How to sell your home

Top tips from property investors

Clinigen agrees to buy U.S. rights to Novartis' cancer drug Proleukin

Reuters

(Reuters) - British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of $210 million (163 million pounds), including some future payments.

The deal will give Clinigen global rights to the drug and the company expects the deal to add to its profitability this year, and forecast a growth in adjusted EBITDA for the six months ended December.

(This story corrects headline and paras 1 and 2 to clarify that deal has been agreed but not yet completed).

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Gopakumar Warrier)